MRNA Vaccine: How to Meet the Challenge of SARS-CoV-2

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Feb 7

PMID 35126377

Authors

Yingqi Jin

Chen Hou

Yonghao Li

Kang Zheng

Chuan Wang

Affiliations

Soon will be listed here.

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high infectivity, pathogenicity, and variability, is a global pandemic that severely affected public health and the world economy. The development of safe and effective vaccines is crucial to the prevention and control of an epidemic. As an emerging technology, mRNA vaccine is widely used for infectious disease prevention and control and has significant safety, efficacy, and high production. It has received support and funding from many pharmaceutical enterprises and becomes one of the main technologies for preventing COVID-19. This review introduces the current status of SARS-CoV-2 vaccines, specifically mRNA vaccines, focusing on the challenges of developing mRNA vaccines against SARS-CoV-2, and discusses the relevant strategies.

Citing Articles

Functionally Designed Nanovaccines against SARS-CoV-2 and Its Variants.

Xi Y, Ma R, Li S, Liu G, Liu C Vaccines (Basel). 2024; 12(7).

PMID: 39066402 PMC: 11281565. DOI: 10.3390/vaccines12070764.

Novel receptor, mutation, vaccine, and establishment of coping mode for SARS-CoV-2: current status and future.

Zeng Z, Geng X, Wen X, Chen Y, Zhu Y, Dong Z Front Microbiol. 2023; 14:1232453.

PMID: 37645223 PMC: 10461067. DOI: 10.3389/fmicb.2023.1232453.

Advancements in the development of nucleic acid vaccines for syphilis prevention and control.

Li S, Li W, Jin Y, Wu B, Wu Y Hum Vaccin Immunother. 2023; 19(2):2234790.

PMID: 37538024 PMC: 10405752. DOI: 10.1080/21645515.2023.2234790.

Machine Learning Classification of Time since BNT162b2 COVID-19 Vaccination Based on Array-Measured Antibody Activity.

Ma Q, Huang F, Guo W, Feng K, Huang T, Cai Y Life (Basel). 2023; 13(6).

PMID: 37374086 PMC: 10305362. DOI: 10.3390/life13061304.

Glutathione deficiency in the pathogenesis of SARS-CoV-2 infection and its effects upon the host immune response in severe COVID-19 disease.

Labarrere C, Kassab G Front Microbiol. 2022; 13:979719.

PMID: 36274722 PMC: 9582773. DOI: 10.3389/fmicb.2022.979719.

References

Kim J, Eygeris Y, Gupta M, Sahay G . Self-assembled mRNA vaccines. Adv Drug Deliv Rev. 2021; 170:83-112. PMC: 7837307. DOI: 10.1016/j.addr.2020.12.014. View

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

Tiboni M, Casettari L, Illum L . Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?. Int J Pharm. 2021; 603:120686. PMC: 8099545. DOI: 10.1016/j.ijpharm.2021.120686. View

Bahl K, Senn J, Yuzhakov O, Bulychev A, Brito L, Hassett K . Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses. Mol Ther. 2017; 25(6):1316-1327. PMC: 5475249. DOI: 10.1016/j.ymthe.2017.03.035. View

Yu J, Tostanoski L, Peter L, Mercado N, McMahan K, Mahrokhian S . DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020; 369(6505):806-811. PMC: 7243363. DOI: 10.1126/science.abc6284. View

Perry C, Luttwak E, Balaban R, Shefer G, Morales M, Aharon A . Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv. 2021; 5(16):3053-3061. PMC: 8362658. DOI: 10.1182/bloodadvances.2021005094. View

Lu J, Lu G, Tan S, Xia J, Xiong H, Yu X . A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Res. 2020; 30(10):936-939. PMC: 7429369. DOI: 10.1038/s41422-020-00392-7. View

Baral P, Bhattarai N, Hossen M, Stebliankin V, Gerstman B, Narasimhan G . Mutation-induced changes in the receptor-binding interface of the SARS-CoV-2 Delta variant B.1.617.2 and implications for immune evasion. Biochem Biophys Res Commun. 2021; 574:14-19. PMC: 8364676. DOI: 10.1016/j.bbrc.2021.08.036. View

Kannan S, Shaik Syed Ali P, Sheeza A . Evolving biothreat of variant SARS-CoV-2 - molecular properties, virulence and epidemiology. Eur Rev Med Pharmacol Sci. 2021; 25(12):4405-4412. DOI: 10.26355/eurrev_202106_26151. View

10.

Collier D, Ferreira I, Kotagiri P, Datir R, Lim E, Touizer E . Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021; 596(7872):417-422. PMC: 8373615. DOI: 10.1038/s41586-021-03739-1. View

11.

Maruggi G, Zhang C, Li J, Ulmer J, Yu D . mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases. Mol Ther. 2019; 27(4):757-772. PMC: 6453507. DOI: 10.1016/j.ymthe.2019.01.020. View

12.

Sherman S, Smith L, Sim J, Amlot R, Cutts M, Dasch H . COVID-19 vaccination intention in the UK: results from the COVID-19 vaccination acceptability study (CoVAccS), a nationally representative cross-sectional survey. Hum Vaccin Immunother. 2020; 17(6):1612-1621. PMC: 8115754. DOI: 10.1080/21645515.2020.1846397. View

13.

Wadman M . The overlooked superpower of mRNA vaccines. Science. 2021; 373(6554):479. DOI: 10.1126/science.373.6554.479. View

14.

Young Chung J, Thone M, Kwon Y . COVID-19 vaccines: The status and perspectives in delivery points of view. Adv Drug Deliv Rev. 2020; 170:1-25. PMC: 7759095. DOI: 10.1016/j.addr.2020.12.011. View

15.

Garcia-Beltran W, Lam E, St Denis K, Nitido A, Garcia Z, Hauser B . Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021; 184(9):2372-2383.e9. PMC: 7953441. DOI: 10.1016/j.cell.2021.03.013. View

16.

Soiza R, Scicluna C, Thomson E . Efficacy and safety of COVID-19 vaccines in older people. Age Ageing. 2020; 50(2):279-283. PMC: 7799251. DOI: 10.1093/ageing/afaa274. View

17.

Kuchar E, Zaleski A, Wronowski M, Krankowska D, Podsiadly E, Brodaczewska K . Children were less frequently infected with SARS-CoV-2 than adults during 2020 COVID-19 pandemic in Warsaw, Poland. Eur J Clin Microbiol Infect Dis. 2020; 40(3):541-547. PMC: 7520378. DOI: 10.1007/s10096-020-04038-9. View

18.

Yang S, Li Y, Dai L, Wang J, He P, Li C . Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021; 21(8):1107-1119. PMC: 7990482. DOI: 10.1016/S1473-3099(21)00127-4. View

19.

Jackson L, Anderson E, Rouphael N, Roberts P, Makhene M, Coler R . An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020; 383(20):1920-1931. PMC: 7377258. DOI: 10.1056/NEJMoa2022483. View

20.

Chavda V, Vora L, Pandya A, Patravale V . Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management. Drug Discov Today. 2021; 26(11):2619-2636. PMC: 8319039. DOI: 10.1016/j.drudis.2021.07.021. View